SB-228357
SB-228357 is a serotonin receptor agonist that was discovered and developed by SmithKline Beecham. It is a potent and selective 5-HT4 receptor agonist, with a pKi of 9.5, and has been used in scientific research to study the function of the 5-HT4 receptor.
History[edit]
SB-228357 was first discovered and developed by the pharmaceutical company SmithKline Beecham. The compound was identified as a potent and selective 5-HT4 receptor agonist, which made it a valuable tool in scientific research to study the function of the 5-HT4 receptor.
Pharmacology[edit]
SB-228357 is a potent and selective 5-HT4 receptor agonist. The 5-HT4 receptor is one of the several different subtypes of the serotonin receptor, which is a group of G protein-coupled receptors that are targeted by a variety of drugs used in the treatment of various disorders, including depression, anxiety, and migraine.
Research[edit]
SB-228357 has been used in scientific research to study the function of the 5-HT4 receptor. The compound's potent and selective agonist activity at the 5-HT4 receptor makes it a valuable tool in this research.
See also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
References[edit]
External links[edit]
SB-228357[edit]
-
SB-228357 structure
